To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Rizatriptan (Maxalt®) is a triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
Additional recommended knowledge
Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.
Rizatriptan is available only by prescription in the United States and Canada. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom.
This medication is used to treat acute migraine attacks. It does not prevent future migraine attacks.
Ear, nose, and throat:
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rizatriptan". A list of authors is available in Wikipedia.|